{"disease":{"id":"hunter-syndrome","name":"hunter syndrome"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03292887","title":"Hunter Outcome Survey (HOS)","phase":"","overall_status":"COMPLETED","enrollment_count":1443,"lead_sponsor_name":"Shire","has_results":false},{"nct_id":"NCT02171104","title":"MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":149,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT01822184","title":"Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II)","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Shire","has_results":false},{"nct_id":"NCT00630747","title":"Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT02055118","title":"Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT02412787","title":"Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT00937794","title":"Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase®","phase":"","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT03920540","title":"A Study of GC1111 in Hunter Syndrom Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Green Cross Corporation","has_results":false},{"nct_id":"NCT07344376","title":"An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"GC Biopharma Corp","has_results":false},{"nct_id":"NCT00607386","title":"Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT00882921","title":"An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients","phase":"","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT02455622","title":"Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT00920647","title":"A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT01506141","title":"An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT01330277","title":"Biomarkers for Hunter Syndrome","phase":"","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"CENTOGENE GmbH Rostock","has_results":false},{"nct_id":"NCT01449240","title":"Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome","phase":"","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT04976231","title":"MPS II Immunophenotyping","phase":"","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT06031259","title":"Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT03582449","title":"Intensive Pharmacovigilance Program for Elaprase (SHP ELA-701)","phase":"","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"Shire","has_results":false},{"nct_id":"NCT05058391","title":"A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in India","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT07236606","title":"RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)","phase":"PHASE3","overall_status":"SUSPENDED","enrollment_count":2,"lead_sponsor_name":"REGENXBIO Inc.","has_results":false},{"nct_id":"NCT05494593","title":"A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)","phase":"PHASE4","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT05795361","title":"Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Takeda","has_results":false}],"total":23},"guidelines":[],"source":"Drug Landscape verified database"}